A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies
- Conditions
- Lymphoma, Non-HodgkinLymphoma, Large B-Cell, DiffuseLymphoma, Follicular
- Interventions
- First Posted Date
- 2017-10-16
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Celgene
- Target Recruit Count
- 62
- Registration Number
- NCT03310619
- Locations
- 🇺🇸
Local Institution - 015, Omaha, Nebraska, United States
🇺🇸Local Institution - 016, Philadelphia, Pennsylvania, United States
🇺🇸Local Institution - 011, Duarte, California, United States
Radiolabeled Study of CC-220 in Healthy Male Subjects
- First Posted Date
- 2017-09-27
- Last Posted Date
- 2017-10-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 6
- Registration Number
- NCT03294603
- Locations
- 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States
A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment.
- First Posted Date
- 2017-09-21
- Last Posted Date
- 2020-07-17
- Lead Sponsor
- Celgene
- Target Recruit Count
- 31
- Registration Number
- NCT03290443
- Locations
- 🇺🇸
New Orleans Center of Clinical Research, Knoxville, Tennessee, United States
🇺🇸DaVita Clinical Research, Minneapolis, Minnesota, United States
🇺🇸Clinical Pharmacology of Miami, LLC, Miami, Florida, United States
Post Marketing Surveillance on Safety Evaluation of POMALYST® (Pomalidomide) Treatment of Multiple Myeloma in Korea
- First Posted Date
- 2017-09-20
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Celgene
- Target Recruit Count
- 397
- Registration Number
- NCT03288974
- Locations
- 🇰🇷
Korea University Ansan Hospital, Ansan, Korea, Republic of
🇰🇷Inje University Busan Paik Hospital, Busan, Korea, Republic of
🇰🇷Chungnam National University Hospital, DaeJeon, Korea, Republic of
Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors
- Conditions
- Diffuse B-Cell Lymphoma
- Interventions
- First Posted Date
- 2017-09-14
- Last Posted Date
- 2021-04-29
- Lead Sponsor
- Celgene
- Target Recruit Count
- 35
- Registration Number
- NCT03283202
- Locations
- 🇪🇸
Hospital Universitario Virgen Del Rocio, Sevilla, Spain
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Washington University, Saint Louis, Missouri, United States
A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors
- Conditions
- MedulloblastomaCentral Nervous System Neoplasms
- Interventions
- First Posted Date
- 2017-08-22
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Celgene
- Target Recruit Count
- 53
- Registration Number
- NCT03257631
- Locations
- 🇫🇷
Local Institution - 101, Villejuif CEDEX, France
🇪🇸Local Institution - 302, Barcelona, Spain
🇫🇷Local Institution - 105, Vandoeuvre les Nancy, France
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas
- First Posted Date
- 2017-07-18
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Celgene
- Target Recruit Count
- 139
- Registration Number
- NCT03220347
- Locations
- 🇮🇹
Local Institution - 302, Rozzano (MI), Italy
🇪🇸Local Institution - 202, Madrid, Spain
🇫🇷Local Institution - 102, Bordeaux, France
A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence
- First Posted Date
- 2017-06-21
- Last Posted Date
- 2023-08-24
- Lead Sponsor
- Celgene
- Target Recruit Count
- 95
- Registration Number
- NCT03194542
- Locations
- 🇺🇸
Local Institution - 109, Cleveland, Ohio, United States
🇺🇸Local Institution - 100, Houston, Texas, United States
🇺🇸MD Anderson Cancer Center The University of Texas, Houston, Texas, United States
A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus
- First Posted Date
- 2017-05-19
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Celgene
- Target Recruit Count
- 289
- Registration Number
- NCT03161483
- Locations
- 🇺🇸
North Shore-LIJ Health System-Division of Rheumatology, Great Neck, New York, United States
🇺🇸University Of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Integral Rheumatology and Immunology Specialists, Plantation, Florida, United States
A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis
- Conditions
- Idiopathic Pulmonary FibrosisFibrosisIdiopathic Interstitial PneumoniasPathologic ProcessesLung Diseases, InterstitialLung DiseasesRespiratory Tract Diseases
- Interventions
- Other: Placebo
- First Posted Date
- 2017-05-05
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Celgene
- Target Recruit Count
- 138
- Registration Number
- NCT03142191
- Locations
- 🇺🇸
Local Institution - 502, Dallas, Texas, United States
🇺🇸University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
🇺🇸University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States